Bristol-Myers Squibb Q2 Revenue Beats Expectations, Raises Full-Year Guidance
Alina Collins
Bristol-Myers Squibb posted Q2 revenue of $12.7 billion, beating consensus by over $1.2 billion, with adjusted EPS topping estimates by $0.44; the company sharply raised full-year revenue and earnings guidance, both well above Wall Street consensus.
How big was the earnings beat?
Q2 revenue hit $12.7 billion, up 5.7% year-over-year, roughly $1.23 billion above analyst estimates.
Adjusted EPS came in at $2.04, beating expectations by $0.44 — This means → the profit beat was proportionally larger than the revenue beat, pointing to favorable cost control or product mix.
In plain terms = Wall Street already expected a strong quarter, and the actual numbers still left those expectations behind.
How much did full-year guidance rise?
Full-year revenue guidance moved from $46.0–47.5 billion to $49.0–50.0 billion, a midpoint increase of roughly $2.7 billion.
Full-year adjusted EPS guidance rose from $6.05–6.35 to $6.75–7.00; prior analyst consensus stood at just $6.34.
This means → management's confidence extends beyond one quarter — they see multiple product lines sustaining volume gains through the second half.
Which drugs are driving the growth?
The Growth Portfolio — BMY's designated newer-drug lineup — delivered $7.56 billion in Q2 revenue, up 15%, with nine products posting double-digit growth.
Blood thinner Eliquis led the way: Q2 sales of $4.48 billion, up 22%, beating estimates by $420 million. U.S. new-prescription share is approaching 80%. BMY raised Eliquis's full-year growth forecast from 10–15% to 20–25%.
Cardiac drug Camzyos ($416M, beat), anemia treatment Reblozyl ($735M, beat), and cancer cell therapy Breyanzi ($484M, beat) — all three came in well above consensus.
How much drag do legacy drugs create?
Flagship cancer immunotherapy Opdivo posted Q2 sales of $2.49 billion, down 3% year-over-year, slightly below expectations.
Former top seller Revlimid (blood cancer) plunged 49% to $425 million, driven by generic competition.
The legacy portfolio as a whole declined roughly 4% — This reflects the ongoing revenue erosion once key patents expire.
How is the Opdivo transition progressing?
BMY is actively shifting patients from IV-infusion Opdivo to subcutaneous Opdivo Qvantig. Qvantig posted Q2 revenue of $261 million, beating estimates of $215 million.
Combined Opdivo + Qvantig sales are growing at a mid-single-digit rate; the IV-to-subcutaneous conversion rate has reached roughly 15%.
In plain terms = the total Opdivo franchise is still expanding — growth is simply migrating from the old formulation to the new one. The higher the conversion rate climbs, the stronger BMY's future pricing power.
Can new drugs keep outrunning legacy losses?
The core equation: the Growth Portfolio is expanding at double digits while the legacy portfolio is shrinking at low-to-mid single digits — for now, new gains outpace old losses.
This means → as long as the Growth Portfolio maintains its current trajectory, the raised guidance is credible. But if Eliquis growth slows or generic erosion accelerates, the balance tips quickly.
All nine double-digit growers are in early lifecycle stages, and continued volume ramp is the foundation for any valuation premium the market assigns.
Content is for reference only, not financial advice.